NEW YORK / Jan 09, 2025 / Business Wire / Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, will release its fourth quarter and full year 2024 financial results after the market closes on Tuesday, February 4, 2025.
Management will review these results in a conference call beginning at 5:00 PM (ET). The call-in number and webcast link are as follows:
Live Call: 1.855.761.5600
Conference ID: 7768132
Webcast
The call will be archived and available on Oscar’s investor relations website (ir.hioscar.com) following February 4, 2025 for a period of 90 days.
About Oscar Health
Oscar Health, Inc. (“Oscar”) is a leading healthcare technology company built around a full stack technology platform and a relentless focus on serving our members. We have been challenging the status quo in the healthcare system since our founding in 2012, and are dedicated to making a healthier life accessible and affordable for all. Oscar offers Individual & Family plans and health technology solutions that power the healthcare industry through +Oscar. Our technology drives superior experiences, deep engagement, and high-value clinical care, earning us the trust of approximately 1.65 million members, as of September 30, 2024.
Last Trade: | US$12.35 |
Daily Change: | -0.10 -0.80 |
Daily Volume: | 2,648,372 |
Market Cap: | US$2.620B |
February 04, 2025 November 07, 2024 August 22, 2024 August 07, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load